1-6 of 6
Holly M. Horton
Close
Sort by
Journal Articles

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

James B Rottman, DVM, PhD DACVP, Kenneth Ganley, BS, Brenna Daly, BS, Holly M. Horton, PhD, Kevin M. Friedman, Molly Perkins, PhD, Shannon Grande, PhD, Claire J Rhodes, BS, Richard A. Morgan, PhD, Christopher J. Horvath, DVM, MS, DACVP
Journal: Blood
Blood (2017) 130 (Supplement 1): 4450.
https://doi.org/10.1182/blood.V130.Suppl_1.4450.4450
Published: 2017
Journal Articles

A Drug-Regulated CAR Platform (DARIC) Induces Effective and Reversible Tumor Control In Vivo Using Non-Immunosuppressive Rapamycin Dosing

Wai-Hang Leung, PhD, Michael T Certo, PhD, Holly M. Horton, PhD, Joel Gay, Tracy VandenBerg, Jordan Jarjour, PhD, Alexander Astrakhan, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1910.
https://doi.org/10.1182/blood.V130.Suppl_1.1910.1910
Published: 2017
Journal Articles

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil., Shannon Grande, PhD, Amanda Hamel, BS, Holly M. Horton, PhD, Tracy E. Garrett, BA, Sara M. Miller, Howard J. Latimer, IV, BS, Christopher J. Horvath, DVM, MS, DACVP, Michael Kuczewski, MS, Kevin M. Friedman, PhD, Richard A. Morgan, PhD
Journal: Blood
Blood (2015) 126 (23): 1893.
https://doi.org/10.1182/blood.V126.23.1893.1893
Published: 2015
Journal Articles

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Alena A. Chekmasova, PhD, Holly M. Horton, PhD, Tracy E. Garrett, BA, John W. Evans, PhD, Johanna Griecci, BS, Amanda Hamel, BS, Howard J. Latimer, IV, BS, Stacie L. Seidel, MA, Byoung Y. Ryu, PhD, Michael Kuczewski, MS, Christopher J. Horvath, DVM, MS, DACVP, Kevin M. Friedman, PhD, Richard A. Morgan, PhD
Journal: Blood
Blood (2015) 126 (23): 3094.
https://doi.org/10.1182/blood.V126.23.3094.3094
Published: 2015
Journal Articles

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

Yu-Tzu Tai, Holly M. Horton, Sun-Young Kong, Erik Pong, Hsing Chen, Saso Cemerski, Matthew J. Bernett, Duc-Hanh T. Nguyen, Sher Karki, Seung Y. Chu, Greg A. Lazar, Nikhil C. Munshi, John R. Desjarlais, Kenneth C. Anderson, Umesh S. Muchhal
Journal: Blood
Blood (2012) 119 (9): 2074–2082.
https://doi.org/10.1182/blood-2011-06-364521
Published: 2012
Includes: Supplemental data
Journal Articles

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

Holly M. Horton, Matthew J. Bernett, Matthias Peipp, Erik Pong, Sher Karki, Seung Y. Chu, John O. Richards, Hsing Chen, Roland Repp, John R. Desjarlais, Eugene A. Zhukovsky
Journal: Blood
Blood (2010) 116 (16): 3004–3012.
https://doi.org/10.1182/blood-2010-01-265280
Published: 2010